Nuevocor, a pre-clinical stage biotechnology company, announced on Thursday that it has named Dr John Lee, MD, PhD, as its new chief Medical officer.
Dr Lee, a life science executive, has more than 15 years of clinical development and regulatory experience from early drug discovery to late-stage clinical development. He has most recently served as the chief medical officer of PhaseBio Pharmaceuticals. He has served as vice president, global head, Cardiovascular Center of Excellence at Quintiles and executive director, Discovery Medicine at Bristol-Myers Squibb, and has served in leadership roles in both biotech and pharmaceutical sectors.
Dr Yann Chong Tan, PhD, CEO and co-founder of Nuevocor, said, 'Dr Lee's appointment marks a significant milestone for Nuevocor. His extensive experience and proven track record in clinical development make him the ideal candidate to lead our clinical development team. His leadership will be instrumental in furthering our commitment to advancing science and translating it into therapies that will make a real difference in patients' lives.'
Nordic Bioscience launches new Endotrophin assay
AbbVie and ADARx Pharmaceuticals partner on next-generation siRNA therapies
Otsuka's leukaemia drug ponatinib launched on Fangzhou platform
FDA accepts Novo Nordisk's filing application for oral semaglutide 25 mg
Avacta Therapeutics reports positive Phase 1 data for lead candidate
Innovent's limertinib receives Chinese regulatory approval for first-line treatment of lung cancer
Primo Biotechnology's Taoyuan facility granted PIC/S GMP Certification
Renibus Therapeutics completes RBT-1 Phase 3 clinical trial enrolment
Rona Therapeutics granted Chinese approval of IND application for hypertension drug candidate RN1871
Clario partners with AWS on advancing clinical data analysis with generative AI
Langhua Pharmaceutical passes US FDA's on-site inspection
Abbott receives CE Mark for Volt Pulsed Field Ablation System to treat atrial fibrillation
Ionis announces partnership expansion with Sobi for global olezarsen commercialisation